key: cord-0949131-2nlb57mn
authors: Achiron, Anat; Gurevich, Michael; Falb, Rina; Dreyer-Alster, Sapir; Sonis, Polina; Mandel, Mathilda
title: SARS-COV-2 antibody dynamics and B-cell memory response over-time in COVID-19 convalescent subjects
date: 2021-05-08
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.05.008
sha: 1722c1158974e731ec483b06ad4f4d3aedf9ce3a
doc_id: 949131
cord_uid: 2nlb57mn

OBJECTIVES: Worldwide spread of COVID-19 disease highlights the need for assessment of long-term humoral immunity in convalescent subjects. Our objectives were to evaluate long-term IgG SARS-CoV-2 antibody response and B-cell memory response in COVID-19 convalescent subjects. METHODS: Blood samples were collected from a cohort of subjects recovering from COVID-19 disease and from healthy subjects that donated blood. SARS-CoV-2 IgG antibodies were quantitatively detected by ELISA using anti-S1 spike IgG. SARS-CoV-2 spike-specific IgG memory B-cells were evaluated in a randomly selected group of COVID-19 recovering subjects by reversed B-cell FluroSpot based on human IgG SARS-CoV-2 receptor-binding domain. Statistical analysis was performed with clinical variables and time post-COVID-19 infection. RESULTS: Antibody response was not detected in 26 of 392 (6.6%) COVID-19 convalescent subjects. Over a period of 9 months, the level of antibodies decreased by 50% but stabilized at 6 months and prevailed a protective level up to 9 months. No differences were found regarding IgG SARS-COV-2 antibody levels for age, gender, and major blood types, over-time. COVID-19 asymptomatic subjects did not differ in antibody level overtime from subjects with mild to severe disease. Repeated paired IgG SARS-COV-2 antibody level analyses disclosed that over 6 and 9 months, 15.3% (9 of 59) and 15.8% (3 of 19) of subjects became SARS-COV-2 IgG seronegative, respectively, all with low antibody level at 3 months. Rate of antibody decline was not affected by age, gender, or clinical symptomatology. In a subgroup of recovering subjects, memory B-cell response up to 9-months post COVID-19 infection, was undetectable in 31.8% (14/44) of subjects with no correlation to age, SARS-COV-2 antibody level, or time post-infection. CONCLUSIONS: Majority of COVID-19 convalescent subjects develop IgG SARS-COV-2 antibody response that prevails a protective level over a period of up to 9-months regardless of age, gender, major blood types or clinical symptomatology.

Coronavirus disease 2019 (COVID-19) is a devastating severe disease responsible for over 140 million infections since its emergence in December 2019, leading to high rate of morbidity and mortality [1] . The basis of protective immunity after infections includes the production of antigen specific antibody response, and the generation of memory adaptive immune response mediated by B and T-cells [2, 3] . Little is known about the development of long-term humoral immunity and the generation of memory B cells following COVID-19 infection, or the ease to activate humoral immune response during recurrent infection. Factors that determine the fate of activated B cells after primary antigen encounter need to be investigated to shed light on the following: (1) whether COVID-19 infection can lead to sustained antibody protection and whether the absence of specific S1 spike antibodies necessarily mean absence of immune response; (2) what is the longevity of this humoral response; and (3) 

Blood samples were collected from a cohort of subjects recovering from COVID-19 disease and from healthy subjects that donated blood.

Convalescent subjects were recruited through local networking and local media, and all had a prior diagnosis of COVID-19 disease by positive reverse transcriptase polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 RNA nasopharyngeal swab. Antibody response was measured at multiple time points defined as months after positive SARS-CoV-2 RNA nasopharyngeal swab, as follows: 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, and 8-9 months. In a sub-cohort the same subjects were followed over time and samples were collected respectively.

This study was approved by Sheba Institutional Review Board SMC-750320) and informed consent was obtained from all enrolled participants. Each patient record was coded for anonymity to ensure confidentiality during statistical analyses.

Immunoassay for the detection of SARS-CoV-2 IgG antibodies in blood samples was performed using Euroimmun (EI, Lubeck, Germany) anti-J o u r n a l P r e -p r o o f SARS-CoV-2 IgG quantitative ELISA kit based on a recombinant S1 subunit of the SARS-CoV-2 spike protein. The test has a sensitivity of 90% and specificity of 100%. Tests were performed in accordance with manufacturer instructions, using AGILITY® automated ELISA analyzer (DYNEX Technologies Inc., Chantilly, VA), and optical density was measured at 450 nm. Results are presented at a grange from 0 to 15, and a value higher than 0.8 was considered positive [4] .

Analysis was performed at various time periods following positive RT-PCR detection of SARS-CoV-2 RNA nasopharyngeal swab. 

Continuous variables were evaluated for a normal distribution and described as medians and interquartile ranges (IQRs). Categorical months. In 59 subjects two serial measurements were performed and in 19 COVID-19 convalescent subjects three serial measurements were obtained (Fig 2A and 2B , respectively). Multivariate linear regression analysis disclosed that the only variable that predicted the decay of IgG SARS-CoV-2 antibodies over time was the previous IgG SARS-CoV-2 antibody level. The rate of IgG SARS-CoV-2

In a randomly selected group of 44 convalescent COVID-19 subjects median (25-75 IQR) 32.3 (19.2-47.9) years, 31 males, B cell memory response analyzed 1 to 9 months post infection was detected in 68.2% of subjects. There were no differences related to SARS-CoV-2 IgG level, time post infection or age between subjects with or without SARS-CoV-2 spikespecific IgG memory B-cell response.

Understanding the pathway of immune regulation following COVID-19 infection has important implications to recovering patients and healthcare authorities regarding decisions related to safety behavior in daily life and the need for vaccination. Our findings that 6.6% of COVID-19 convalescent subjects did not develop IgG SARS-COV-2 antibodies are in accordance with previous studies [4, 5] .

The failure of infected subjects to mount an effective primary immune response can be attributed to false-positive RT-PCR results but can also suggest that, similarly to many other infections, some patients have immune barriers possibly related to antigen capture that prevent a proper humoral response. Further research is needed to unveil factors that lead to such failure.

Our findings demonstrated long-lasting protective humoral immunity against COVID-19 by S1 IgG antibodies in most COVID-19 convalescent subjects.

We used the Euroimmune ELISA assay to quantify SARS-COV-2 antibody level as it was reported to highly correlate with the neutralizing antibody assay [6, 7] . It is well known that high neutralizing titers are particularly important for protection against the COVID-19 pandemic [8] .

This immune response was sustained up to 9 months post-infection. The level of humoral protection was not affected by age, gender, blood type or, clinical symptomatology, as both asymptomatic and subjects with mild to severe disease had developed immune responses with similar levels of SARS-CoV-2 IgG antibodies. Although we observed a time-related antibody decline by 50% over a period of 9 months, the antibody level in most convalescent COVID-19 subjects was still in the protective range and reached a sustained plateau at 6 months that remained stable up to 9 months post-infection.

We found no significant differences in SARS-CoV-2 IgG antibodies levels between female and male convalescent subjects over time. This finding is in agreement with a recent study that reported no gender differences in 331 COVID-19 recovering patients following the early post-infection period [9] , although a previous small study of 42 COVID-19 convalescent subjects with only 4 females reported that the generation of IgG antibodies was higher in females in the disease early phase [10] . It has J o u r n a l P r e -p r o o f been reported that regardless of age, females tend to show greater antibody responses, higher basal Ig levels, and higher B cell numbers than do males [11] . However, these gender-related immune differences were not observed following COVID-19 infection. [11] .

The absence of clinical symptomatology in COVID-19 infected subjects was reported to be associated with lower virus-specific IgG levels and a higher rate of seroconversion in the early convalescent phase [12] . Our findings, in contrast, demonstrated that asymptomatic COVID-19 convalescent subjects developed similar levels of SARS-CoV-2 IgG to that of symptomatic subjects, and the decline over time was similar in both groups.

A recent study reported that there were no significant differences in antispike IgG titers by ABO blood group [13] . Similarly, we did not find any association between the level of SARS-CoV-2 IgG antibodies and blood groups.

Previous studies reported low rates of seroconversion within the early period (2-3 months) post-infection, mainly in patients who had low IgG antibodies from the beginning or were immunosuppressed [14, 15] . We The absence of specific S1 spike antibodies in the serum does not necessarily mean the absence of immune response. Antibody titers might not be the only determining factor for judging the success of COVID-19 immunization. It is possible that memory B cells can operate and provide a secondary immune response during a future encounter with SARS-Cov-2 infection. Another possibility is that patients who became negative for SARS-COV-2 IgG antibodies may still have SARS-CoV-2-specific memory T-cells [16] . We failed to observe a correlation between circulating IgG titers and memory B cell numbers. We found SARS-CoV-2 spike-specific IgG memory B-cell response only in 68.2% of subjects, regardless of IgG antibody level or the time post-infection. It is evident that COVID-19 convalescent subjects that maintain both high SARS-CoV-2 antibodies and memory B-cell are best protected from recurrent infection.

Subjects that lost their antibodies but still hold a memory B-cell response, are expected to have a milder disease when re-infected, as memory humoral immunity can provide long protection despite effector humoral decay.

The problem remains regarding convalescent subjects that maintain SARS-CoV-2 IgG antibody response in the absence of B-cell memory response. Is it possible that serum antibodies will persist in the absence of memory B-cells and provide life-long protection? Or should these group that comprises more than a third of convalescent subjects need to be vaccinated despite prior COVID-19 infection? Is it possible that following vaccination they will develop antigen-specific memory B-cells that will induce a long-lasting immune response?

The limitations of the study are the lack of longitudinal assessments for the majority of the subjects as only 78/392 (19.9%) have serial samples.

The interval between the two and three repeated antibody measurements in the same subjects, though variable, adds valuable data to show a protective level up to 9 months post-infection. Another limitation of the study is the missing knowledge regarding the role of memory T-cells especially in patients that did not develop humoral immunity.

Our findings may help adopt COVID-19 vaccination strategies in relation to time post-infections and specifically regarding subjects that over time 

Defining the Epidemiology of Covid-19 -Studies Needed

Dying in a Leadership Vacuum

Memory B cells: effectors of long-lived immune responses

Adaptive immunity to SARS-CoV-2 and COVID-19

Anti-SARS-CoV-2 ELISA IgG, Package Insert. EI_2606G_A_US_C02.docx Version

Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients

Antibody tests for identification of current and past infection with SARS-CoV-2

Correlation between SARS-COV-2 antibody screening by immunoassay and neutralizing antibody testing

Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays

Longitudinal profiling of antibody response in patients with COVID-19 in a tertiary care hospital in Beijing, China. Front Immunol

Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individualsfrom India

A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex

In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. Vox Sang

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Humoral Immune Response to SARS-CoV-2 in Iceland

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19